At the recent SupplySide West 2019 in Las Vegas, representatives of BI Nutraceuticals discussed the ingredient on everyone’s mind in the natural products industry: CBD. BI Nutraceuticals’ CEO, George Pontiakos, and its director of extract manufacturing, Michael Wagner, Ph.D., sat down for a podcast interview with Josh Long, legal and regulatory editor of Natural Products INSIDER. In the podcast, Pontiakos and Wagner discussed:
- Challenges sourcing quality CBD products
- Few companies, Pontiakos said, “have all the controls in place to ensure that what you’re providing to the consumer is correct, safe and efficacious.”
- Safety concerns related to farming practices and extraction
- Said Pontiakos: “A vast majority of hemp growers are brand new to the industry. Many of them never grew a tomato in their back yard let alone had a commercial farming operation.”
- Commenting on extraction, Wagner said companies may lack the technical expertise to eliminate residual solvents from their extracts. “That’s a serious concern that we see in other extracts. It applies exactly to this and when you have inexperienced people doing it, you run that risk.”
- The potential for adverse reactions from the combination of CBD products and prescription drugs
- Whether FDA should establish a dosing limitation for CBD in dietary supplements
- The eventual maturation of the market
- “Those that are in it today,” Pontiakos said, “may not be there tomorrow when the bigger players decide to come in.”
Got feedback? Email Josh Long at [email protected]
0 comments
Hide comments